



HORIZONCME PRESENTS

STOP Cancer

Summit for Novel Therapeutics in Oncology &
Precision Medicine in Cancer

SEPTEMBER 25 -27, 2025

Four Seasons Hotel
Las Vegas



REGISTER AT
HORIZONCME.COM

STOP Cancer

CONFERENCE OVERVIEW

The Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer) is a multidisciplinary conference that brings together clinicians, scientists, researchers, and pharmaceutical industry experts in the field of oncology to provide and gain insight into recent advances in cancer science and medicine. The primary aim of the conference is to discuss recent advancements, challenges, and future directions in the areas of novel therapeutic agents and drug discovery, clinical trial design, molecular profiling, and precision oncology. STOP Cancer will highlight the latest in early phase research and interpretation and application of precision medicine.

REGISTRATION FEES:

Designation	Advance (Ends August 26, 2025 at 11:59 p.m. Pacific time)	Standard (Begins August 27, 2025 at 12:00 a.m. Pacific time)
MD, DO, PhD	\$490	\$590
Allied Health (NP, PA, RN, PharmD, Fellows, Residents, Retired)	\$275	\$375
Industry**	\$790	\$890

Register Today at **HORIZONCME.COM**



CONFERENCE COMMITTEE:



Hani Babiker, MD
COURSE DIRECTOR

Pancreaticobiliary, GI Oncology, Early Phase Therapeutics, and Senior Associate Consultant
Mayo Clinic
Jacksonville, FL



Patricia LoRusso, DO

Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics
Yale Cancer Center
New Haven, CT



Elena Garraida, MD

Medical Oncologist,
Director, Early Drug Development Unit,
Co-Director of VHIO's Clinical Research Program
Director of the Phase I Unit,
Vall d'Hebron Institute of Oncology, NEXT Oncology
Barcelona, Spain



Mitesh Borad, MD

Associate Professor of Medicine
Mayo Clinic
Scottsdale, AZ



Toshio Shimizu, MD, PhD

Professor, Wakayama Medical University Hospital/WMUH
Cancer Center Department of Pulmonary Medicine and Medical Oncology Wakayama Medical University
Graduate School of Medicine Wakayama, Japan



Eytan M. Stein, MD

Chief, Leukemia Service Director,
Program for Drug Development in Leukemia,
Division of Hematologic Malignancies,
Memorial Sloan Kettering Cancer Center,
New York, NY